Vaccination News

Moderna this week said preliminary clinical trial data confirmed that its updated COVID-19 vaccine provides a “significant boost” in neutralizing antibodies against emerging SARS-CoV-2 viruses and is expected to effectively target them.

The FDA extended the review period for Valneva’s chikungunya vaccine candidate by 3 months while the design of a phase 4 study is finalized.

The prevalence of long COVID has stabilized since January 2023, with roughly one in 10 adults with previous COVID-19 experiencing some form of the condition, a recent study showed.

The EG.5 omicron subvariant has emerged as the predominant SARS-CoV-2 virus during a summer wave of COVID-19 in the Unted States, accounting for 17.3% of cases, according to CDC tracking.

Although both are safe and effective, the Moderna COVID-19 vaccine was linked to greater protection and a slightly lower risk for adverse events compared with the Pfizer-BioNTech vaccine in older adults, data in JAMA Network Open show.

Healio | Infectious Disease News Editorial Board Member Jeanne M. Marrazzo, MD, MPH, was appointed director of the National Institute of Allergy and Infectious Diseases, replacing Anthony S. Fauci, MD, who stepped down in December.

The CDC has recommended that infants be immunized with a monoclonal antibody against respiratory syncytial virus.

This fall, older adults in the United States will have the opportunity to receive three vaccines to against fall and winter season respiratory illnesses — COVID-19, influenza and respiratory syncytial virus. 

This coming fall and winter, older adults in the United States will face a decision: Should they roll up their sleeves to receive the world’s first approved vaccines against respiratory syncytial virus?

One in six toddlers in the United States did not complete the vaccination series for seven recommended childhood vaccines in 2019, the year before the COVID-19 pandemic, according to a study published in Pediatrics.